- Home
- OPCH vs CORT Comparison
OPCH vs CORT Comparison
Compare OPCH & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | CORT |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 1996 | 2001 |
Fundamental Metrics
Financial Performance| Metric | OPCH | CORT |
|---|---|---|
| Price | $19.56 | $51.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $36.57 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 3.5M | 991.4K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,998,202,000.00 | $761,407,000.00 |
| Revenue This Year | $7.21 | $26.08 |
| Revenue Next Year | $8.55 | $26.98 |
| P/E Ratio | $68.66 | ★ N/A |
| Revenue Growth | ★ 16.17 | 12.79 |
| 52 Week Low | $18.01 | $28.66 |
| 52 Week High | $36.80 | $91.00 |
Technical Indicators
Market Signals| Indicator | OPCH | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 21.62 | 68.88 |
| Support Level | $18.01 | $32.95 |
| Resistance Level | $29.13 | $90.00 |
| Average True Range (ATR) | 0.97 | 2.02 |
| MACD | -0.50 | 0.10 |
| Stochastic Oscillator | 13.27 | 82.84 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.